PSTVPLUS THERAPEUTICS, INC.

Nasdaq plustherapeutics.com


$ 2.17 $ 0.00 (0 %)    

Thursday, 09-May-2024 10:08:02 EDT
QQQ $ 439.56 $ -0.90 (-0.2 %)
DIA $ 391.79 $ 1.68 (0.43 %)
SPY $ 517.97 $ 0.53 (0.1 %)
TLT $ 89.88 $ -0.16 (-0.18 %)
GLD $ 216.07 $ 1.23 (0.57 %)
$ 2.27
$ 2.17
$ 2.10 x 100
$ 2.46 x 200
$ 2.17 - $ 2.17
$ 0.97 - $ 5.09
234,886
na
7.13M
$ 1.25
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-05-2024 12-31-2023 10-K
2 10-31-2023 09-30-2023 10-Q
3 08-14-2023 06-30-2023 10-Q
4 04-20-2023 03-31-2023 10-Q
5 02-23-2023 12-31-2022 10-K
6 10-20-2022 09-30-2022 10-Q
7 07-21-2022 06-30-2022 10-Q
8 04-21-2022 03-31-2022 10-Q
9 02-24-2022 12-31-2021 10-K
10 10-21-2021 09-30-2021 10-Q
11 07-22-2021 06-30-2021 10-Q
12 04-22-2021 03-31-2021 10-Q
13 02-22-2021 12-31-2020 10-K
14 10-22-2020 09-30-2020 10-Q
15 08-10-2020 06-30-2020 10-Q
16 05-14-2020 03-31-2020 10-Q
17 03-30-2020 12-31-2019 10-K
18 11-14-2019 09-30-2019 10-Q
19 08-15-2019 06-30-2019 10-Q
20 05-14-2019 03-31-2019 10-Q
21 03-29-2019 12-31-2018 10-K
22 11-14-2018 09-30-2018 10-Q
23 08-14-2018 06-30-2018 10-Q
24 05-11-2018 03-31-2018 10-Q
25 03-09-2018 12-31-2017 10-K
26 11-09-2017 09-30-2017 10-Q
27 08-11-2017 06-30-2017 10-Q
28 05-12-2017 03-31-2017 10-Q
29 03-24-2017 12-31-2016 10-K
30 11-09-2016 09-30-2016 10-Q
31 08-05-2016 06-30-2016 10-Q
32 05-10-2016 03-31-2016 10-Q
33 03-11-2016 12-31-2015 10-K
34 11-06-2015 09-30-2015 10-Q
35 08-10-2015 06-30-2015 10-Q
36 05-11-2015 03-31-2015 10-Q
37 03-16-2015 12-31-2014 10-K
38 11-07-2014 09-30-2014 10-Q
39 08-11-2014 06-30-2014 10-Q
40 05-12-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 micro-cap-brain-cancer-focused-plus-therapeutics-poised-to-receive-3m-from-us-department-of-defense

Plus Therapeutics will secure $3 million in funding from the Department of Defense for pediatric brain cancer trial expansion.

 plus-therapeutics-announces-validation--clinical-implementation-of-csf-01-leptomeningeal-cancer-cell-diagnostic

Plus' CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma an...

 plus-therapeutics-q4-eps-070-beats-107-estimate-sales-131m-beat-106m-estimate

Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(1...

 earnings-scheduled-for-march-5-2024

Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2...

 plus-therapeutics-says-the-award-payment-of-33m-together-with-its-cash-on-hand-provides-sufficient-runway-to-fund-operations-to-2h-2025

The Company forecasts an additional $6.9 million in grant revenue during the 2024 calendar year.

 insiders-buying-plus-therapeutics-and-2-other-stocks-under-2

The Dow Jones closed lower by around 40 points on Wednesday. When insiders purchase or sell shares, it indicates their confiden...

 why-plus-therapeutics-stock-popped-today

PLUS THERAPEUTICS, Inc. (NASDAQ: PSTV) shares are trading higher on Wednesday.

 why-extreme-networks-shares-are-trading-lower-by-around-15-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Gainers

 why-plus-therapeutics-shares-are-trading-higher-by-over-11-here-are-20-stocks-moving-premarket

Gainers

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION